The novel IGF-IR/Akt-dependent anticancer activities of glucosamine

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Song, Ki Hoon ^a   Kang, Ju Hee ^a,b   Woo, Jong Kyu ^c   Nam, Jeong Seok ^c   Min, Hye Young ^d   Lee, Ho Young ^d   Kim, Soo Youl ^a   Oh, Seung Hyun ^c  

^a National Cancer Center   (South Korea)

^b Chung Ang University   (South Korea)

^c Gachon University   (South Korea)

^d Seoul National University   (South Korea)

Author keywords

Akt; Anticancer agent; ER stress; Glucosamine; Glycosylation; IGF 1R

Indexed keywords

CYCLOOXYGENASE 2; GLUCOSAMINE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; GLYCOSYLATION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPLASMIC RETICULUM STRESS; GLUCOSAMINE; GLYCOSYLATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; PHOSPHORYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84892455034     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-31     Document Type: Article

References (35)

1. Quastel JH, Cantero A. Inhibition of tumour growth by D-glucosamine. Nature 1953, 171(4345):252-254. 10.1038/171252a0, 13036842.
2. Koch HU, Schwarz RT, Scholtissek C. Glucosamine itself mediates reversible inhibition of protein glycosylation. A study of glucosamine metabolism at inhibitory concentrations in influenza-virus-infected cells. Eur J Biochem 1979, 94(2):515-522. 10.1111/j.1432-1033.1979.tb12920.x, 570921.
3. Morin MJ, Porter CW, McKernan P, Bernacki RJ. The biochemical and ultrastructural effects of tunicamycin and D-glucosamine in L1210 leukemic cells. J Cell Physiol 1983, 114(2):162-172. 10.1002/jcp.1041140204, 6822608.
4. Yushok WD. Inhibition of glucolysis and fructolysis of Krebs 2 ascites carcinoma cells by chemical agents. Cancer Res 1958, 18(8 Part 2):379-389.
5. Sukeno T, Kikuchi H, Saeki H, Tsuiki S. Transformation of glucosamine to glycogen and lactate by ascites tumor cells. Biochim Biophys Acta 1971, 244(1):19-29. 10.1016/0304-4165(71)90116-4, 4330425.
6. Bekesi JG, Winzler RJ. The effect of D-glucosamine on the adenine and uridine nucleotides of sarcoma 180 ascites tumor cells. J Biol Chem 1969, 244(20):5663-5668.
7. Bosmann HB. Inhibition of protein, glycoprotein, ribonucleic acid and deoxyribonucleic acid synthesis by D-glucosamine and other sugars in mouse leukemic cells L5178Y and selective inhibition in SV-3 T3 compared with 3 T3 cells. Biochim Biophys Acta 1971, 240(1):74-93. 10.1016/0005-2787(71)90515-6, 4329927.
8. Masson E, Lagarde M, Wiernsperger N, El Bawab S. Hyperglycemia and glucosamine-induced mesangial cell cycle arrest and hypertrophy: common or independent mechanisms?. IUBMB Life 2006, 58(7):381-388. 10.1080/15216540600755980, 16801212.
9. Ju Y, Yu A, Sun X, Wu D, Zhang H. Glucosamine, a naturally occurring amino monosaccharide, inhibits A549 and H446 cell proliferation by blocking G1/S transition. Mol Med Rep 2013, 8(3):794-798.
10. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501. 10.1038/nrc839, 12094235.
11. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002, 296(5573):1655-1657. 10.1126/science.296.5573.1655, 12040186.
12. Franke TF. PI3K/Akt: getting it right matters. Oncogene 2008, 27(50):6473-6488. 10.1038/onc.2008.313, 18955974.
13. Jang BC, Sung SH, Park JG, Park JW, Bae JH, Shin DH, Park GY, Han SB, Suh SI. Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner. J Biol Chem 2007, 282(38):27622-27632. 10.1074/jbc.M610778200, 17635918.
14. Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009, 273(2):243-249. 10.1016/j.canlet.2008.08.015, 18804908.
15. Oh HJ, Lee JS, Song DK, Shin DH, Jang BC, Suh SI, Park JW, Suh MH, Baek WK. D-glucosamine inhibits proliferation of human cancer cells through inhibition of p70S6K. Biochem Biophys Res Commun 2007, 360(4):840-845. 10.1016/j.bbrc.2007.06.137, 17624310.
16. Park JY, Park JW, Suh SI, Baek WK. D-glucosamine down-regulates HIF-1alpha through inhibition of protein translation in DU145 prostate cancer cells. Biochem Biophys Res Commun 2009, 382(1):96-101. 10.1016/j.bbrc.2009.02.129, 19254699.
17. Kantor ED, Lampe JW, Peters U, Shen DD, Vaughan TL, White E. Use of glucosamine and chondroitin supplements and risk of colorectal cancer. Cancer Causes Control 2013, 24(6):1137-1146. 10.1007/s10552-013-0192-2, 23529472.
18. Han JY, Oh SH, Morgillo F, Myers JN, Kim E, Hong WK, Lee HY. Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005, 97(17):1272-1286. 10.1093/jnci/dji251, 16145048.
19. Krug E, Zweibaum A, Schulz-Holstege C, Keppler D. D-glucosamine-induced changes in nucleotide metabolism and growth of colon-carcinoma cells in culture. Biochem J 1984, 217(3):701-708. 1153271, 6712593.
20. Wang Z, Liang R, Huang GS, Piao Y, Zhang YQ, Wang AQ, Dong BX, Feng JL, Yang GR, Guo Y. Glucosamine sulfate-induced apoptosis in chronic myelogenous leukemia K562 cells is associated with translocation of cathepsin D and downregulation of Bcl-xL. Apoptosis 2006, 11(10):1851-1860. 10.1007/s10495-006-9529-6, 16850161.
21. Lee HT, Kay EP. Regulatory role of PI 3-kinase on expression of Cdk4 and p27, nuclear localization of Cdk4, and phosphorylation of p27 in corneal endothelial cells. Invest Ophthalmol Vis Sci 2003, 44(4):1521-1528. 10.1167/iovs.02-0637, 12657588.
22. Yeh J, Litz J, Hauck P, Ludwig DL, Krystal GW. Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt. Lung Cancer 2008, 60(2):166-174. 10.1016/j.lungcan.2007.09.023, 18006183.
23. Davidson MB, Hunt K, Fernandez-Mejia C. The hexosamine biosynthetic pathway and glucose-induced down regulation of glucose transport in L6 myotubes. Biochim Biophys Acta 1994, 1201(1):113-117. 10.1016/0304-4165(94)90159-7, 7918574.
24. Qiu W, Su Q, Rutledge AC, Zhang J, Adeli K. Glucosamine-induced endoplasmic reticulum stress attenuates apolipoprotein B100 synthesis via PERK signaling. J Lipid Res 2009, 50(9):1814-1823. 10.1194/jlr.M800343-JLR200, 2724794, 19383982.
25. Werstuck GH, Khan MI, Femia G, Kim AJ, Tedesco V, Trigatti B, Shi Y. Glucosamine-induced endoplasmic reticulum dysfunction is associated with accelerated atherosclerosis in a hyperglycemic mouse model. Diabetes 2006, 55(1):93-101. 10.2337/diabetes.55.01.06.db05-0633, 16380481.
26. Tomida A, Suzuki H, Kim HD, Tsuruo T. Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells. Oncogene 1996, 13(12):2699-2705.
27. Zhang L, Liu WS, Han BQ, Peng YF, Wang DF. Antitumor activities of D-glucosamine and its derivatives. J Zhejiang Univ Sci B 2006, 7(8):608-614. 10.1631/jzus.2006.B0608, 1533750, 16845712.
28. Calvo MB, Figueroa A, Pulido EG, Campelo RG, Aparicio LA. Potential role of sugar transporters in cancer and their relationship with anticancer therapy. Int J Endocrinol 2010, 2010:1-14.
29. Zachara NE, Hart GW. The emerging significance of O-GlcNAc in cellular regulation. Chem Rev 2002, 102(2):431-438. 10.1021/cr000406u, 11841249.
30. Slawson C, Zachara NE, Vosseller K, Cheung WD, Lane MD, Hart GW. Perturbations in O-linked beta-N-acetylglucosamine protein modification cause severe defects in mitotic progression and cytokinesis. J Biol Chem 2005, 280(38):32944-32956. 10.1074/jbc.M503396200, 16027160.
31. Han I, Kudlow JE. Reduced O glycosylation of Sp1 is associated with increased proteasome susceptibility. Mol Cell Biol 1997, 17(5):2550-2558. 232104, 9111324.
32. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27(41):5497-5510. 10.1038/onc.2008.245, 3398461, 18794884.
33. Berglind H, Pawitan Y, Kato S, Ishioka C, Soussi T. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol Ther 2008, 7(5):699-708. 10.4161/cbt.7.5.5712, 18277095.
34. Sun SY, Yue P, Mao L, Dawson MI, Shroot B, Lamph WW, Heyman RA, Chandraratna RA, Shudo K, Hong WK, et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000, 6(4):1563-1573.
35. Ouyang X, Wang X, Xu K, Jin DY, Cheung AL, Tsao SW, Wong YC. Effect of p53 on centrosome amplification in prostate cancer cells. Biochim Biophys Acta 2001, 1541(3):212-220. 10.1016/S0167-4889(01)00157-4, 11755215.